Scripps La Jolla First in U.S. to Use ZOLL’s FDA-approved Supersaturated Oxygen Therapy on Patients Suffering From Widowmaker Heart Attacks
ASAHI KAISEI CRP UNSP/ADR (AHKSY)
NASDAQ:AMEX Investor Relations:
asahi-kasei.co.jp/asahi/en/ir
Company Research
Source: Business Wire
First and Only Treatment to Reduce Heart Muscle Damage Following Angioplasty and Stenting CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today that Scripps Memorial Hospital La Jolla, in San Diego, Calif., treated its first “widowmaker” heart attack patient with SuperSaturated Oxygen (SSO2) Therapy. This is the first-of-a-kind FDA-approved device proven through randomized clinical trials to reduce heart muscle damage.1SSO2 Therapy delivers hyperbaric levels of oxygen directly to the damaged heart muscle immediately after successful revascularization via angioplasty and stenting of the blocked coronary artery. It is indicated for patients who suffer the most serious kind of heart attack, left anterior descending ST-elevation myocardial infarction (LAD STEMI) — also known as a “widowmaker” due to the high mortality rate — and are treated within six hours of symptom
Show less
Read more
Impact Snapshot
Event Time:
AHKSY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AHKSY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AHKSY alerts
High impacting ASAHI KAISEI CRP UNSP/ADR news events
Weekly update
A roundup of the hottest topics
AHKSY
News
- Asahi Kasei Pharma Strengthens Global Reach with Exclusive License Agreement for anti-CX3CR1 AntibodyBusiness Wire
- Car users’ concerns to define interior of fully autonomous cars, citing 5th Global Automotive Consumer Survey by Asahi KaseiBusiness Wire
- Asahi Kasei Receives 2024 TSMC Excellent Performance Award in Recognition of Its Pimel™ Photosensitive Dielectric for Advanced Semiconductor PackagingBusiness Wire
- Licensee of Asahi Kasei Technology Begins Commercial Production of High-Purity Carbonates Using CO2 as Main Feedstock in China [Yahoo! Finance]Yahoo! Finance
- Licensee of Asahi Kasei Technology Begins Commercial Production of High-Purity Carbonates Using CO2 as Main Feedstock in ChinaBusiness Wire